Hyloris Pharmaceuticals SA Financials
HYL.XBRU
All currency values in € millions unless otherwise noted
Scroll
| Income Statement | DEC 2025 | DEC 2024 | DEC 2023 | DEC 2022 | DEC 2021 |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenue | €7 | €8 | €2 | €1 | €3 |
| Cost of Revenue | €0 | €0 | €0 | €0 | €0 |
| Gross Profit | €7 | €8 | €2 | €1 | €3 |
| Research & Development | €11 | €10 | €14 | – | – |
| Total Operating Expenses | €14 | €15 | €18 | €12 | €13 |
| Operating Income | -€7 | -€7 | -€16 | -€12 | -€10 |
| Non-Operating | |||||
| Net Interest Expense | -€1 | -€0 | -€0 | -€0 | -€1 |
| Other Non-Operating Income (Expense) | €1 | €1 | €1 | – | – |
| EBT (Earnings Before Tax) | -€7 | -€6 | -€15 | – | – |
| Income Tax Expense | -€0 | €0 | €0 | €0 | €0 |
| Earnings from Continuing Ops | -€6 | -€6 | -€15 | – | – |
| Net Income | |||||
| Net Income | -€6 | -€6 | -€15 | -€12 | -€12 |
| Per Share Data | |||||
| Revenue Per Share | €0.26 | €0.31 | €0.07 | €0.03 | €0.12 |
| EPS (Basic) | -€0.23 | -€0.23 | -€0.55 | -€0.43 | -€0.45 |
| EPS (Diluted) | -€0.23 | -€0.23 | -€0.55 | -€0.43 | -€0.45 |
| Shares Outstanding | 27.5M | 27.6M | 28.0M | 27.2M | 25.8M |
Hyloris Pharmaceuticals SA (HYL.XBRU) financials: revenue, profit and margins
Hyloris Pharmaceuticals SA (HYL.XBRU) generated about €7 million in revenue and -€6 million in net income (a -87.9% net margin) over the trailing twelve months, growing at roughly 23.5% a year. Figures are from company filings; this is analysis, not investment advice.
Frequently asked
What is Hyloris Pharmaceuticals SA's (HYL.XBRU) revenue?+
Hyloris Pharmaceuticals SA generated about €7 million in revenue over the trailing twelve months. Revenue has grown at roughly 23.5% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
Is Hyloris Pharmaceuticals SA profitable?+
Hyloris Pharmaceuticals SA reported about -€6 million in net loss over the trailing twelve months, a net margin of roughly -87.9%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
What are Hyloris Pharmaceuticals SA's profit margins?+
Hyloris Pharmaceuticals SA runs a gross margin of about 94.7%, an operating margin of about -94.5%, a net margin of about -87.9%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.
How fast is Hyloris Pharmaceuticals SA growing?+
Hyloris Pharmaceuticals SA's revenue has compounded at roughly 23.5% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside HYL.XBRU's margins and free cash flow. This is analysis from company filings, not investment advice.
Peers
Biotechnology · Pick stocks to compare with HYL.XBRU
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HYL.XBRU
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.